The interference of the recombinant HIV-1 glycoproteins gp160 and gp120 with the CD3/T cell antigen receptor (TcR)-mediated activation process has been investigated in the CD4+ diphtheria toxoid-specific human P28D T cell clone. Both glycoproteins clearly inhibit the T cell proliferation induced in an antigen-presenting cell (APC)-free system by various cross-linked monoclonal antibodies specific for the CD3 Introduction HIV-1 infection in humans results in quantitative and qualitative defects in the CD4 helper/inducer T cell function (1). The selective infection of CD4+ T cells by HIV-1 is governed through the high affinity interaction between the viral envelope glycoprotein gp 120 and T cell surface expressed determinants of the CD4 molecule. Different works showed that soluble gp 120 itself could exert a suppressive effect on T cell responses. Thus, gp 120 could alter the antigen-specific proliferation of human uninfected CD4+ T cells (2-4) thereby
Introduction HIV-1 infection in humans results in quantitative and qualitative defects in the CD4 helper/inducer T cell function (1) . The selective infection of CD4+ T cells by HIV-1 is governed through the high affinity interaction between the viral envelope glycoprotein gp 120 and T cell surface expressed determinants of the CD4 molecule. Different works showed that soluble gp 120 itself could exert a suppressive effect on T cell responses. Thus, gp 120 could alter the antigen-specific proliferation of human uninfected CD4+ T cells (2) (3) (4) thereby probably contributing to a part of the HIV-1 observed immunosuppressive effects. Such proliferative responses require that soluble antigen should be processed by antigen-presenting cells (APC)' and presented to T cells in the context of MHC class II molecules (5) . They also usually require that CD4 on T cells bind to monomorphic epitopes of MHC class II molecules on APC (6) . It was therefore proposed that gpl 20 could competitively block this interaction by binding to CD4. This was further supported by the finding that inhibition of T cell function by gp 120 does not require the cytoplasmic domain of CD4 (4) . Purified CD4+ T cells infected in vitro with HIV-1 have been shown to exhibit a selective signaling defect in their proliferative and biochemical responses to CD3-specific MAbs (7). Gp 120 was also shown to inhibit T cell activation triggered by various mitogens (8) or CD3-specific MAbs in the presence of APC (9) . However, participation of the gp 120 competitive blocking effect in this inhibition remains unclear.
Recent works have shown it to be likely that the CD4 molecule may have a signaling role in human T cells and is perhaps directly involved in signal transduction. The main evidence was that CD4-specific MAbs could inhibit T cell stimulation driven by ligands such as: mitogenic lectins or CD3-specific MAbs (10) (11) (12) . Bank et al. showed that CD4 could deliver inhibitory signals to T cells independent of MHC class II recognition (13). It was therefore suggested that binding of gpl20 to CD4 may also transmit negative signals to T cells (9) .
In this report, a human diphtheria toxoid (DT)-specific CD4+ T cell clone was used to investigate how purified HIV-1 glycoproteins gpl 60s and gp 1 20s could alter the CD3/T cell antigen receptor (TcR)-transducing biochemical pathway mediated independent of accessory cells by MAbs specific both for the TcR a/f heterodimer or the CD3 molecule.
Methods
Reagents. Myo- [2-3H] inositol (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) Ci/mmol) and [32Pjorthophos-phoric acid (carrier free) were from Amersham International, Amer- sham, UK. [6-3H] gpl60s was purified by gel filtration and reverse HPLC (Kaczorek, M., unpublished results). Gpl20s is a derivative of the HIV-l envelope glycoprotein (6) that was deleted of its gp4l moieties (I15). Expression was obtained as described above by infection of BHK2 1 cells with the vaccinia recombinant virus clone 1132. Secreted gpl20s was purified by gel filtration and affinity lectin chromatography (not published). Purity of both supernatants was greater than 75 and 90%, respectively, as estimated by HPLC and SDS-PAGE (not shown). A control supernatant was purified in the same conditions from BHK21 cells infected with wild-type vaccinia virus. A soluble form of the extracellular moiety of the CD4 protein was produced in CHO cells using previously described procedures (16) . After ammonium sulfate precipitation, resuspended soluble CD4 (sT4) was extensively dialyzed and purified by FPLC on a mono-Q Sepharose column (Pharmacia, Inc., Uppsala, Sweden). Purity of sT4 was > 90% as assessed by SDS-PAGE and FPLC profiles (not shown).
Monoclonal antibodies. CD3-specific MAb X35 (IgG2a), a kind gift of Dr. Bourel, Centre National de Transfusion Sanguine, Rennes, France, and CD2-specific MAbs X 1 and D66, kindly provided by Dr. A. Bernard, Institut Gustave Roussy, Villejuif, France, were previously described (17, 18) . MAbs CD3-4B5 (IgGl) and SMC2 (IgM), both specific for the CD3 molecule, were obtained through the exchanges of the 4th International Workshop and Conference on Human Leukocyte Differentiation Antigens. UCHT1 myeloma cells were kindly given by Dr. P. C. L. Beverley, Imperial Cancer Research Center, London, UK. MAb lC5Va (IgGl) specific for the a chain ofthe P28D TcR was developed in our laboratory (18a). Purified MAbs OKT4 and OKT4a (IgG2a) were from Ortho Pharmaceutical, Raritan, NJ. Gp 110-specific MAb 110.4 was obtained from Genetic Systems Corp., Seattle, WA. All MAbs, except OKT4 and OKT4a, were used as ascitic fluid.
Tcells. Human DT-specific T cell clone P28D was derived from an HLA-DR6/7 healthy individual as previously described (19). It was propagated in complete culture medium consisting of RPMI 1640 supplemented with 5% pooled human serum, 2 mM L-glutamine, 1 mM Na-pyruvate, penicillin, and streptomycin by periodic restimulation with the antigen presented by an autologous EBV-transformed B cell line (B LCL). Recombinant IL-2 (10-20 U/ml) was added every 3 d to maintain cell growth and viability. In all experiments the cells were used at day 14 of the restimulation cycle, 3 d after the last addition of fresh IL-2 (> 95% in the GO/G1 phase of the cell cycle, not shown).
T cell proliferation assays were performed in 96-well flat-bottomed microtiter plates in complete culture medium in a final volume of 200 Ml. 5 X I04 T cells per well were stimulated with the specified MAbs in the presence or absence of gps (4 ,ug/ml). All CD3/TcR-specific MAbs were cross-linked with a 1/400 dilution of a rabbit anti-mouse Ig antiserum. Antigen-specific proliferation assays were carried out in the same conditions with DT (30 gg/ml) using 2. For immunofluorescence analysis, an indirect staining with fluorescein isothiocyanate-conjugated affinity-purified goat anti-mouse IgG Fc fragments (Nordic Immunology, Tilburg, The Netherlands) was used as described (10 MgCl2, and 0.5% glucose, resuspended (107/ml) in the same medium, and incubated in the dark for 30 min at 37°C with membrane-permeable Fura-2 acetoxymethyl ester, 3 MAM (Calbiochem-Behring Corp., San Diego, CA). Cells were then washed and transferred to quartz cuvettes thermostatically controlled at 37°C. Fura-2 fluorescence was recorded on an LS-5B luminescence spectrometer (Perkin-Elmer Corp., Nancy, France) using 10-nm slit widths for both excitation and Intracellular pH measurements. T cells were suspended (107/ml) in PBS, pH 7.2, and incubated with 2.5 jig/ml of the esterified indicator 2',7'-bis42-carboxyethyl)-5-carboxyfluorescein, tetraacetoxymethylester (BCECF/AM) (Calbiochem) at 37°C for 30 min. Loaded cells were then allowed to equilibrate for 30 min in the same medium, washed once, resuspended in 2.5 ml of the same medium, and transferred into a 37°C prewarmed quartz glass cuvette. Agonist was added at the indicated times after establishment of a stable base line. BCECF fluorescence was measured with an LS-5B luminescence spectrometer (Perkin-Elmer) using wavelengths for excitation and emission of 500 and 530 nm, respectively. Calibration of fluorescence signals with intracellular pH (pHi) was carried out using nigericin and K+ medium as described (25) .
Results
gpl6Os and gpJ20s inhibit P28D T cell proliferation triggered via the CD3/TcR molecular complex. Mitogenic responses of T lymphocytes, including resting P28D T cells (not shown) to soluble CD3/TcR-specific MAbs usually depend upon the presence of accessory cells. Since gpl20 has been shown to interfere with the APC-T cell interaction (2, 4) , the CD3/TcRmediated proliferative signal was delivered independent of autologous peripheral blood mononuclear cells by cross-linked antibodies. As shown in Fig. 1 (B), gpl60s and gpl20s inhibit P28D proliferation induced by CD3-specific MAb X35 in a dose-dependent manner (45 to 80% maximal inhibition depending on the experiments, n = 5). Note that HIV-1 glycoproteins used alone did not induce any significant P28D proliferation. In agreement with previous works (2, 4, 9) , the antigen-specific proliferation, performed in parallel with an optimal concentration of DT (30 addition of soluble CD4 sT4 (4 gg/ml) was found to reverse in all cases the gps-induced inhibition. A control supernatant purified from wild-type vaccinia virus-infected BHK21 cells failed to inhibit the P28D proliferative responses to the different CD3-specific MAbs, even at protein concentrations fivefold higher than gps preparations (not shown). Moreover, cell viability, as assessed by trypan blue dye exclusion, was > 98% in control and gps-treated T cells. As suggested in previous studies on HIV-l-infected T cells (7, 26) , the proliferation induced by a mitogenic combination of two CD2-specific MAbs X 1I + D66 was unaffected by gps. These results demonstrate that only the CD3/TcR-stimulating pathway is inhibited by gps in P28D T cells. We therefore conclude that gpl60s and gpl20s specifically inhibit, in an APC-free system, the CD3/TcR pathway leading to T cell proliferation. These results also suggest that the observed inhibitions probably involve a mechanism distinct from or additional to the alteration of the specific interaction between CD4 on T cells and MHC class II determinants on APC.
gpJ60s and gpJ20s inhibit the phosphoinositide transduction pathway mediated via the CD3/TcR but not the CD2. In the T cell activation process, hydrolysis by phospholipase C (PLC) of inositol phospholipids is one ofthe earliest biochemical events triggered by specific antigen (27) or MAbs directed against cell surface activation molecules like the CD3/TcR complex (28) or the CD2 (22, 29). As a result of this enhanced activity of PLC, both an accelerated turnover of phosphoinositides (23) and an increased production of IPs (22, 28) are usually noticed. The results presented above led us to search for a possible inhibitory effect of the HIV-1 glycoproteins on the PLC signaling pathway.
P28D T cells were labeled with [3H]inositol for 24 h and incubated with 4 gg/ml of gpl60s or gpl20s or wild-type vaccinia virus-infected BHK21 cells control supernatant for different periods of time. T cells were stimulated for 30 min with CD3-specific MAb X35 and IPs production was measured. As shown in Fig. 2 , we did not find any significant alteration of the IPs production for short term exposure of P28D T cells to gps. However, a significant inhibition appeared after 6 h of incubation with gpl60s and gpl20s and was usually maximal after 16 h. This time of incubation was chosen to further explore inhibitory effects of both gps on the P28D T cell activation process. Note that IPs formation was not affected at any time in P28D T cells incubated with the control supernatant from BHK21 cells infected with wild-type vaccinia virus. As shown in Fig. 3 (top) only phosphoinositide hydrolysis triggered via the CD3/TcR molecular complex either by specific antigen (DT), presented by DR7,#1-transfected fibroblasts, or by CD3-specific MAb UCHT1 was substantially decreased by a 16-h pretreatment with 4 ig/ml gpl60s (reduction of IPs accumulation up to 60 and 45%, respectively). Incubation with gpl20s led to the same range of inhibitions (not shown). Addition of sT4 during incubation of cells with gps almost completely reversed the observed inhibitory effects. It is important that, in agreement with functional results, the inositol phospholipid hydrolysis triggered by 30 min of stimulation with the CD2-specific MAbs Xl 1 + D66 was identical in control and gps-treated cells. Time-course study showed no inhibition at 5 and 15 min of stimulation by CD2 (not shown). Note that gps alone failed to induce any significant IPs formation.
To confirm these results, PA labeling was measured in 32p_ preincubated P28D T cells, since its increased turnover has been reported as the direct consequence of diacylglycerol (DAG) neosynthesis and phosphorylation during the T cell activation process (29). For this purpose, P28D T cells incubated 16 h with or without gp 160s were labeled near to isotopic equilibrium with 32P and then stimulated for 30 min with MAbs X35 or Xl 1 + D66 (Fig. 3, bottom) that, in addition to their inhibitory effect on the CD3/TcR-induced proliferation, both HIV-I glycoproteins may also specifically impair the CD3/TcR-induced production of phosphatidyl inositol (PI) cycle-related second messengers.
gpJ60s and gpJ20s binding to P28D T cells does not affect CD3/TcR or CD2 cell surface expression. We investigated whether the observed inhibition of the CD3-mediated signaling pathway by gps could be concomitant with a decrease in the cell surface CD3/TcR expression. P28D T cells were incubated with gpl60s for 16 h and immunofluorescence studies were performed. As shown in Fig. 4 , fluorescence analysis of gpl60s-treated cells by gpl 10-specific MAb 110.4 clearly revealed the presence of bound gpl 60s at the P28D cell surface. Analysis with MAb OKT4a, which is known to compete with the binding ofthe viral glycoprotein on the CD4 surface molecule, revealed a markedly reduced level of OKT4a staining on gpl60s-treated as compared with control cells. Gpl60s-binding to CD4 was specific since addition of sT4 (C) could prevent almost completely labeling by MAb 110.4. Greater gp 160s concentrations failed to further block OKT4A staining or increase 110.4 MAb fluorescence, suggesting that saturation of CD4 sites should be complete at 4 ,g/ml (not shown). CD4 was stained with MAb OKT4, which is not affected by gpl20 binding (30) . Reduction of CD4 membrane level (35±4%, n = 4) was seen in the gps-treated P28D cells. It is important that the expression of both the CD3/TcR complex and the CD2 molecule, as monitored with CD3-specific MAb X35 and CD2-specific MAb Xl 1, remained unaltered (identical results with gpl20s, not shown). These findings show that gpl60s efficiently binds to P28D T-cell surface. They further rule out the hypothesis that the inhibitory effect of gpl 60s on the CD3/TcR pathway could be mediated by a decrease in the CD3/TcR membrane levels.
Stability ofgp160s binding to CD4 was also measured. For that purpose P28D T cells were incubated with saturating concentrations of gp 160s for 2 h, washed out, and the expression ofbound gp 160 and CD4 measured as a function oftime. As shown in Table II , CD4 staining remained unaffected while a progressive loss of cell-surface gpl60 could be evidenced and was almost complete at 16 h. At this time, proliferation studies were performed. P28D response to CD3-specific MAbs was unaltered (data not shown).
gpJ20s and gpJ60s inhibit the P28D CD3-mediated Ca2" response. CD3 and CD2-specific MAbs induce a rapid and sustained rise in [Ca2+]J concentration in human T lymphocytes. This is likely to result from activation of the PLC pathway via the CD3/TcR molecule (28, 29). As gps inhibited the CD3-triggered IPs production and PA turnover, we further performed Ca2" measurements on P28D T cells preincubated with gp160s (Fig. 4) . Overnight incubation of P28D T cells with gpl60s could impair by 35±4% (n = 4) the increase in [Ca2+]i induced by the CD3-specific MAb UCHT1 (top left) (among our CD3-specific MAbs, UCHT1 induces the highest P28D Ca2" responses, not shown). Confirming the biochemical data, the Ca2" response to CD2 stimulation was unaffected (top right).
[Ca2+]i increase in CD3 or CD2-stimulated P28D T cells involves both Ca2" mobilization from intracellular stores linked to second messengers ofthe PLC pathway, mainly (1,4, 5) IP3 (28), and Ca2" influx through cell surface voltage-independent Ca2" channels (31) . Ca2+ measurements were further performed in a medium supplemented with 3 mM EGTA. pHi response to CD3 is decreased by gpl60s and gp120s. CD3 and CD2-specific MAbs induce a sustained increase of pH, in P28D T cells within a few minutes. This alkalinization is mainly due to activation of the Na+/H+ membrane exchanger by protein kinase C (PKC) (32). We investigated whether gps could modify the pHi response induced by CD3 and CD2-specific MAbs. As shown in Fig. 6 (bottom) CD3-specific MAb UCHT1-induced alkalinization was clearly decreased in the gps overnight-treated P28D T cells as compared with control cells. This inhibition could be reversed by addition of sT4 (not shown). By contrast, the CD2-induced alkalinization was unaffected (top).
Discussion
We demonstrated in this report that both HIV-I glycoproteins gpl 20s and gpl60s specifically inhibited the proliferative response triggered by various MAbs specific for the TcR a/(3 heterodimer and the CD3 complex of a human CD4+ T cell clone. This inhibition was observed in an APC-free cell system and was therefore clearly independent of APC-T cell interaction. Most previous studies on the effect of HIV on T cell responses dealt with the inhibitory action of gpl 20. However, HIV gp41, which results from the cleavage ofgpl 60 into gpl20 and gp41 moieties, has also been reported to alter T cell function. A gp41-derived 17 mer, pHIVIS, was shown to inhibit lymphocyte proliferation to CD3 in vitro (33). Moreover, a synthetic peptide with sequence identity to gp41 was able to inhibit PKC and anti-CD3-induced Ca2+ influx in Jurkat T cells (34) . However, our data show that both purified recombinant gp 120s and gp 160s similarly impair the response of P28D T cell clone via the CD3/TcR molecule. These findings may (38, 39) . Since CD4 has been identified as the specific receptor for the HIV-l envelope glycoprotein gpl20 (40) , these findings may account for some of the reported inhibitory effects of the viral glycoprotein on the T cell activation process mediated through the human CD3/TcR. In agreement with Weinhold et al. (9) , we found that CD4 expression at the P28D cell surface was not decreased after a 2-h exposure to gp1 20s. However, membrane CD4 levels were reduced after a prolonged exposure to the viral glycoprotein. This was correlated with the time-course of gps-induced inhibitions on P28D T cell responses to CD3 stimulation. As CD4 was also shown to enhance T cell responses to CD3 when brought into close physical proximity to the CD3/TcR complex (12), modulation of CD4 by gps could partially account for the observed impairment in the CD3/TcR-triggered P28D T cell activation. Mittler et al. (41) reported a synergism between gpl20 and IgG fractions from HIV-infected individuals in blocking human T cell activation by formation of complexes that could modulate CD4 membrane levels. Addition of a gp 120-specific MAb failed to increase sensitivity of P28D T cell responses to the inhibitory effects of gps (not shown).
Veillette et al. (42) and Rudd et al. (43) have recently reported in both the murine and the human systems that the CD4 receptor was associated with the protein-tyrosine kinase activity ppS6 ck. The former (44) also showed that cross-linking of the CD4 receptor with CD4-specific MAbs induced a rapid increase in this activity associated with the phosphorylation of the zeta subunit of the CD3 multimeric complex. Function of p561Ck is not known but it was suggested that it could be a component of the signal transduction system regulating T cell activation. However, gpl20 failed to induce phosphorylation of CD4 (45). It is clear in our system that only long-term exposure of T cell clone P28D to gps induced anti-CD3 unresponsiveness. These observations therefore make the involvement of pp56lck in the observed effect of gps very elusive.
Studies of Lamarre et al. (46, 47) showed that gpl20 and MHC class II molecules may interact with distinct but close regions on the CD4. Finally, it is conceivable from our results that gps binding to CD4 may interfere with the normal CD3/ TcR activation process by two distinct, but not mutually exclusive, mechanisms, involving inhibition of APC-T cell interaction and direct transmission of negative signals via the CD4 in the absence of APC. There is no clear evidence for detectable amounts of soluble gpl2O in blood of infected patients. However, we can expect from our in vitro results that low levels of gpl20 that may be released from HIV-infected T cells (1) and adsorbed on the T cell surface in the absence of virus production could partially explain the observed impairment of uninfected T cells' function, especially at early stages of the disease. This may be of importance when considering HIV-1 envelope glycoproteins in vaccinal strategies.
